AstraZeneca and Ionis Wainua Trial Fails Primary Goal in ATTR-CM

Key Facts

In a development highlighting the high risks of rare disease drug development, AstraZeneca and Ionis Pharmaceuticals announced disappointing Phase 3 trial results. According to reports, the drug Wainua (eplontersen) failed to meet its primary endpoint for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The clinical trial results did not demonstrate sufficient efficacy compared to existing treatments, creating a potential setback for the companies' growth guidance in this therapeutic area.

This clinical failure occurs amid intensifying competition from major peers such as Alnylam Pharmaceuticals and Pfizer, which hold approved or late-stage treatments for the same condition. Per market data, failing to meet primary goals often leads to a downward revision of future revenue forecasts associated with the pipeline, especially as analysts had positioned Wainua as a key growth driver within the biopharmaceutical sector.

Regarding stock performance, AZN.L closed at 13140 GBX on July 10, 2026, while the US-listed AZN closed at $178.49 on July 9, 2026. Investors are now watching for further management commentary regarding the drug's future, while also monitoring broader economic catalysts such as the upcoming Eurozone Retail Sales data to gauge general sentiment in European equity markets.